We are proud to announce that CORE-008 has opened Cohort B, this trial is for patients who are high-risk BCG-Exposed NMIBC. If you are interested in participating in this trial, or have an appropriate patient for enrollment, please fill out this questionnaire and an employee of CG Oncology will reach out to you via phone to discuss.
